Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)

Spyre Therapeutics has reported Operating Leases for 5 years, with the latest figure at $3.8 million in Q1 2023.

• For the quarter ending Q1 2023, Operating Leases fell 14.42% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2023 stood at $3.8 million (down 14.42% YoY), and the FY2022 full-year result was $4.0 million, down 13.11% from the prior year.
• Operating Leases for Q1 2023 stood at $3.8 million, down from $4.0 million in the prior quarter.
• The five-year high for Operating Leases was $5.1 million in Q4 2020, with the low at $372000.0 in Q1 2019.
• Historically, Operating Leases has averaged $4.4 million across 5 years, with a median of $4.7 million in 2019.
• Annual changes were most pronounced in 2020 — Operating Leases soared 1194.35% — and 2023, when it retreated 14.42%.
• Spyre Therapeutics' Operating Leases stood at $4.7 million in 2019, then advanced by 8.85% to $5.1 million in 2020, then slipped by 10.16% to $4.6 million in 2021, then dropped by 13.11% to $4.0 million in 2022, then fell by 4.52% to $3.8 million in 2023.
• The last three Operating Leases figures came in at $3.8 million (Q1 2023), $4.0 million (Q4 2022), and $4.2 million (Q3 2022), per Business Quant data.